Please use this identifier to cite or link to this item:
Title: Therapeutic potential of interleukin-6 antagonism in bipolar disorder
Citation: MEDICAL HYPOTHESES, v.76, n.1, p.21-23, 2011
Abstract: Bipolar disorder (BD) is a chronic, severe, and highly disabling psychiatric disorder. Its underlying neurobiology remains largely unclear. A significant body of evidence indicates that inflammatory activation expressed by increased cytokines is relevant in its pathophysiology. IL-6 is one of the most important cytokines involved in the pathogenesis of immune and inflammatory disorders. Several studies recently showed increased levels of IL-6 in manic and depressive episodes and also during euthymia in subjects with BD. Tocilizumab is an IL-6 receptor antagonist being marketed for the treatment of rheumatoid arthritis and Castleman's disease. In this article we discuss the possibility that tocilizumab may have a therapeutic role in treatment of BD through its anti-inflammatory action.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPS
Departamento de Psiquiatria - FM/MPS

Artigos e Materiais de Revistas Científicas - LIM/21
LIM/21 - Laboratório de Neuroimagem em Psiquiatria

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.